ORGO.US Organogenesis Holdings Inc

Healthcare Biotechnology USA Stocks
0.8031 USD
Close of Nov 17, 2026
0.7300 5.91
Market cap
USD 104M
P/E
-
P/B
0.88x
ROE
-206.1%
Dividend yield
10.91%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ORGO.US undervalued?

Graham number

The Graham number of Organogenesis Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Organogenesis Holdings Inc fundamental analysis

No fundamental analysis for Organogenesis Holdings Inc yet.

Organogenesis Holdings Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Organogenesis Holdings Inc

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin subs…

Full company profile